)
Visual
test
Alembic Pharmaceuticals
Alembic Pharmaceuticals (APLLTD) investor relations material
Alembic Pharmaceuticals Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary5 Feb, 2026
Executive summary
Q3 FY26 revenue grew 11% year-over-year to INR 1,876 crore, driven by volume expansion, new launches, and growth in next year markets, with Ex-US Generics leading at 36% growth.
Gross margin for the quarter was 72%, down from 74% last year, but within the targeted 70%-75% range.
EBITDA before R&D and exceptional items rose 20% year-over-year to INR 464 crore, representing 25% of revenue; EBITDA margin for Q3 FY26 was 16%.
Profit after tax before exceptional items increased 21% year-over-year to INR 168 crore; reported PAT was down 4% due to a one-time INR 42 crore provision for labor code changes.
Unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2025 were approved, with statutory auditor review reports issued without qualification.
Financial highlights
Q3 FY26 revenue: INR 1,876.31 crore (+11% YoY); nine-month revenue: INR 5,497.18 crore (+12% YoY).
R&D expenses for the quarter rose 33% year-over-year to INR 165 crore, now at 9% of revenue.
Net working capital at INR 2,944 crore, stable versus September; net debt declined to INR 1,213 crore.
Other income for the quarter was INR 15.5 crore, mostly from Forex gains.
Earnings per share (consolidated) for Q3 FY26 was ₹6.76.
Outlook and guidance
India business expected to return to market growth rate by Q1 of the next fiscal year, driven by operational execution.
U.S. business projected to grow 10-12% for the full year, with mid-teens growth possible in FY27-28.
US Branded business to launch Pivya in Q4, aiming to expand branded drug footprint.
R&D spend to remain at 8-9% of revenue.
The company continues to monitor regulatory changes, especially regarding the new Labour Codes.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and robust acquisitions. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position.
Next Alembic Pharmaceuticals earnings date
Q4 25/268 May, 2026
Alembic Pharmaceuticals
Next Alembic Pharmaceuticals earnings date
Q4 25/268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Alembic Pharmaceuticals Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic and specialty medicines. The company produces active pharmaceutical ingredients (APIs) and formulations across various therapeutic areas, including cardiology, dermatology, neurology, and anti-infectives. The company is headquartered in Vadodara, India, and its shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage